Table 4 Clinical application of antibody in T cell lymphoma
From: Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application
Lymphoma subtypes | Author | PMID/doi | Biomarker | Liquid Biopsy | Method | No. of patients | Results | Clinical applications |
|---|---|---|---|---|---|---|---|---|
ALCL | Mussolin, L et al. [163] | 18615104 | ALK antibody | PB | RT-PCR, NPM::ALK immunocytochemical, ALK antibody titers | 28 | risk of relapse: MDD positivity (more than 10 NCNs NPM::ALK) and antibody titer ≤ 1/2250 vs remaining patients, 62.5% vs 15% (P = 0.02) | MRD |
ALK-positive ALCL | Mussolin, L et al. [164] | 22907048 | ALK antibody | PB | RT-PCR, NPM::ALK immunocytochemical, ALK antibody titers | 128 | MDD + : 59% anti-ALK response + : 96% prognosis: high risk (bHR): MDD-positive and antibody titer ≤ 1/750, 26/128 (20%), PFS 28%, OS 71% low risk (bLR): MDD negative and antibody titer > 1/750, 40/128 (31%), PFS 98%, OS 98% intermediate risk (bIR): all remaining patients, 62/128 (48%), PFS 68%, OS 83% (P = 0.02) | prognosis |
ALK-positive ALCL | Iijima-Yamashita, Yuka et al. [165] | 29030834 | ALK antibody | PB | RT-PCR, real-time PCR (qPCR), NPM::ALK immunocytochemical, ALK antibody titers | 60 | Fifty-two percent were MDD + : RT-PCR 52%. 37% pts > 10NCNs 51% pts antibody titer > 1/750 PFS: high risk (HR): MDD-positive and antibody titer ≤ 1/750, 5/8, 2-year PFS 30% low risk (LR): MDD negative and antibody titer > 1/750, 0/11, 2-year PFS 100% intermediate risk (IR): all remaining patients, 1/15, 2-year PFS 93.3% P = 0.001 | MRD prognosis |